Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC

NCT06456515 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: Regorafenib and Sintilimab in combination with electroacupuncture

Sponsor

The First People's Hospital of Changzhou